Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2003
03/06/2003US20030045544 Bactericides for the oral region of animals using 3-carboxy-4-oxo quinoline or 1,8-naphthyridine derivatives or 1-cyclopropyl-3-carboyx-4-oxo quinolizine derivatives
03/06/2003US20030045543 Systems and methods for treating a mucosal surface
03/06/2003US20030045541 GABA-Receptor modulators with NMDA-Antagonistic activity
03/06/2003US20030045540 Nicotinic acetylcholine receptors antagonists; central nervous system disorder treatments
03/06/2003US20030045539 Cabergoline and pramipexole: new uses and combinations
03/06/2003US20030045537 4-(Phenylamino)-[1,4]dioxano[2,3-g]quinazoline derivatives and process for preparing the same
03/06/2003US20030045535 Antiproliferative and antitumor agents
03/06/2003US20030045534 Pharmaceutical combination of antiviral agents
03/06/2003US20030045533 Phosphodiesterase 4 inhibitors
03/06/2003US20030045532 Triazolo-pyrimidine derivatives as ligands for gaba receptors
03/06/2003US20030045530 Administering a piperazine or piperidine coupled through a linker to a benzhydril
03/06/2003US20030045529 Method for specifically potentiating N-type Ca2+ channel activity
03/06/2003US20030045528 Antibacterial and antiprotozoal agents
03/06/2003US20030045527 Treating central nervous system or gastrointestinal disorders
03/06/2003US20030045525 Particularly in the treatment of benign prostatic hyperplasia.
03/06/2003US20030045524 Particularly quinoxaline, (2-imidozolin-2-ylamino) quinoxaline, or 5-bromo-6-(2-imidozolin-2-ylamino) quinoxaline and linolenic acid, which may be complexed with the quinoxaline agonist
03/06/2003US20030045523 Nicotinic cholinergic receptor antagonists
03/06/2003US20030045522 Novel galenical form for oral administration with prolonged release of molsidomine
03/06/2003US20030045521 Sulfohydroxamic acids and sulfohydroxamates and their use as MEK inhibitors
03/06/2003US20030045519 Treating allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion)
03/06/2003US20030045518 Certain bis(thio-hydrazide amide) compounds significantly enhance the anticancer activity of taxol.
03/06/2003US20030045517 Nonpeptide substituted spirobenzoazepines as vasopressin antagonists
03/06/2003US20030045516 Chemokine receptor antagonists and methods of use therefor
03/06/2003US20030045515 Cyanoguanidine I kappa B kinase inhibitors as antiproliferative agents for cancer treatment
03/06/2003US20030045514 17-Methyleneandrostan-3alpha-ol analogs as CRH inhibitors
03/06/2003US20030045513 Solution comprising: a) water; b) propylene glycol; c) 2-propanol; and d) hydrocortisone; dispensing solution into an external ear canal and contacting a wick with the solution to expand the wick within the canal
03/06/2003US20030045512 Androstanecarbothioic acid derivatives, especially esterified with thazol-5-ylcarboxylic acid; formulation for administration by inhalation
03/06/2003US20030045511 Cyclic combination therapies and regimens utilizing substituted indoline derivative compounds which are antagonists of the progesterone receptor
03/06/2003US20030045510 Estrogen-plus
03/06/2003US20030045509 Hydroxyvitamin D characterized by a purity equal to or greater than 98% by a weight-based HPLC assay, residual solvents of 0.5% or less, a total impurity of 1. 5% or less, and no single impurity of greater than 0.5%.
03/06/2003US20030045508 Phosphoramidates
03/06/2003US20030045506 Fructosamine oxidase: antagonists and inhibitors
03/06/2003US20030045505 Oligosaccharide having at least a D-galactose unit bound by an alpha (1-6) bond with a sucrose unit; second component is a molecule positively charged at physiological pH and that promotes pinocytosis or membrane penetration
03/06/2003US20030045504 Regulation of fat or lipid metabolism by means of compositions and diets which are high in resistant starch and unsaturated fats; especially for treating non-insulin dependent diabetes mellitus.
03/06/2003US20030045503 Topical formulation comprising glucosamine and chondroitin in an anhydrous base that is stable for at least 10 days.
03/06/2003US20030045502 Oral intake solution
03/06/2003US20030045501 Use of atazanavir in HIV therapy
03/06/2003US20030045500 Treating sinus headache or sinus pain; GABA analogs such as gabapentin and pregabalin.
03/06/2003US20030045496 Treating tumor cells with a selenium prodrug lyase and a selenium-containing prodrug such as selenocysteine, selenohomocysteine, selenomethionine or selenoethionine.
03/06/2003US20030045494 Synthetic oligonucleotides complementary to nucleic acids encoding epidermal growth factor
03/06/2003US20030045493 Oligonucleotide compositions and their use to induce differentiation of cells
03/06/2003US20030045490 Therapeutic antisense phosphodiesterase inhibitors
03/06/2003US20030045482 Enables microbiocides to combat infection; protect genes from attack further strengthening the immune system against infection; D-ribose is sprayed on the tongue to curb overeating.
03/06/2003US20030045480 Method of treating hyperresorptive bone disorders
03/06/2003US20030045479 Novel N-formyl hydroxylamine compounds, compositions and methods of use
03/06/2003US20030045473 L-arginine polypeptides thereofor salts or pro-forms and a second component selected from sterols, stanols, sterol esters, stanol esters, and polyol fatty acid polyesters; health bars
03/06/2003US20030045462 Also vectors and host cells comprising those nucleic acid sequences, chimeric molecules of these polypeptides fused to heterologous polypeptide sequences, antibodies which bind to these polypeptides
03/06/2003US20030045461 Composition and methods of esterified nitroxides gated with carboxylic acids
03/06/2003US20030045456 Complex comprising OCIF and polysaccharide
03/06/2003US20030045452 Use of 5-HT4 modulators for the manufacture of a medicament for the treatment of the bladder diseases
03/06/2003US20030045451 Determining or predicting response to cancer therapy in an individual using differential image analysis of immunohistochemically stained tumor samples.
03/06/2003US20030045450 Administering a glycine-site antagonist at the NMDA receptor, e.g., felbamate, for spasticity, symptomatic depression or to protect cells from the consequences of obesity
03/06/2003US20030045449 Pharmaceutical combinations for the treatment of neurodegenerative diseases
03/06/2003US20030044898 Nucleotide sequences coding polypeptide for use in the treatment of asthma, parkinson's, heart defects, hypotension, urogenital and bone disorders
03/06/2003US20030044890 Nucleotide sequences coding polypeptide for use in the treatment of Alzheimer's disease and brain disorders
03/06/2003US20030044888 Polypeptide for use in the treatment of addison's disease
03/06/2003US20030044824 Preincubation assay methods
03/06/2003US20030044813 Diagnosing cancer in humans; obtain tissue, incubate with marker agent, detect signal, evaluate for cancer
03/06/2003US20030044776 Detection of cell death modulators; obtain sample, induce cell death, monitor mitochondrial permeability, detect and evaluate adjustment
03/06/2003US20030044528 Spraying a solution wherein a poorly soluble drug is dissolved in a plasticizer, and an aqueous solution and/or water dispersion of a water-soluble polymer, from nozzle outlets simultaneously and separately.
03/06/2003US20030044514 Using supercritical fluids to infuse therapeutic on a medical device
03/06/2003US20030044479 Process for the production of pure guar meal
03/06/2003US20030044477 Simmondsin processing methods and products
03/06/2003US20030044476 Use for its anti-elastase and anti-inflammatory activity on human gums; chewing gum or gel for treating gingivitis
03/06/2003US20030044475 For cosmetic use for enhancing breast growth and strengthening of the breast tissue, and medical use for suppressing and preventing benign cysts
03/06/2003US20030044474 High molecular weight, lipophilic, orally ingestible bioactive agents in formulations having improved bioavailability
03/06/2003US20030044473 Blood type dietary supplements
03/06/2003US20030044472 Dimethylaminoethanol (DMAE), omega 3-fatty acids, betaine, oligomeric proanthocyanidins (OPC), folic acid, vitamins A, C,E,B12,B6,B5, as well as minerals calcium, magnesium, zinc and selenium
03/06/2003US20030044468 Shaping polymeric precursors by inducing thermal gelation of an aqueous solution thereof and then curing said precursors by crosslinking reactive groups; biomedical uses include drug delivery, microencapsulation, implantation
03/06/2003US20030044466 Oral drug delivery systems where drug is administered with any of specified substances that induce "fed mode" in stomach such as tryptophan dipeptide or cetylpyridinium chloride to prolong retention in stomach; bioavailability
03/06/2003US20030044465 Improving quality of life (QOL) and patient compliance by controlling the in vivo release rate of the drug (2-amino-3-cyano-5-(2-fluorophenyl)-4-methylpyrrole) and also by means of reducing the frequency of taking the drug
03/06/2003US20030044464 Sustained-release, oral pharamaceutical forms of formulation
03/06/2003US20030044462 A pharmaceutical composition in solid form also comprising a stabilizer carboxyvinyl polymer to prevent or inhibit the degradation of bupropion hydrochloride
03/06/2003US20030044461 Antitussive/expectorant compositions
03/06/2003US20030044458 Oral dosage form comprising a therapeutic agent and an adverse-effect agent
03/06/2003US20030044457 Drug delivery device containing oseltamivir and an H1 antagonist
03/06/2003US20030044453 An application to the skin and/or mucosa consisting of active substance solid dispersions in a matrix; reduce skin irritation, efficient drug delivery, improve penetration of hydrophilic medicinal substances through the skin
03/06/2003US20030044452 Composition for topical administration
03/06/2003US20030044446 A multilayered film comprising a first, water-soluble adhesive layer to be placed in contact with a mucosal surface and a second, water-erodible non-adhesive backing layer that controls residence time; drug delivery from mouth
03/06/2003US20030044439 Treatment of skin with adenosine or adenosine analog
03/06/2003US20030044433 Method for preparing submicron suspensions with polymorph control
03/06/2003US20030044419 Use of reagents derived from nucleic acid and amino acid sequences of Int6 gene in diagnostic methods, immunotherapy, gene therapy and as vaccines
03/06/2003US20030044413 Methods of limiting apoptosis of cells
03/06/2003US20030044402 Oligo(ethylene glycol)-terminated 1,2-dithiolanes and their conjugates useful for preparing self-assembled monolayers
03/06/2003US20030044399 Method of treatment
03/06/2003US20030044390 Applying stresses to blood sampling
03/06/2003US20030044381 Synthetic soil-extract materials and medicaments for influenza viruses based thereon
03/06/2003US20030044378 Biocidal polystyrene hydantoin particles
03/06/2003US20030044377 Water, air antiseptic
03/06/2003US20030044363 Protective coatings for skin, hair
03/06/2003US20030044362 Method and product for skin lightening
03/06/2003US20030044360 Blending before applying; containing carbamide peroxide
03/06/2003US20030044356 Composition for nasal solution sprays having effective component of 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one)
03/06/2003US20030044352 Autoimmune disease, anticarcinogenic agents
03/06/2003US20030043544 Integrated cooling system
03/06/2003US20030042870 Intelligent serial battery charger and charging block
03/06/2003US20030042638 Method of solubilizing and encapsulating itraconazole
03/06/2003US20030042202 Low molecular weight thrombin inhibitors
03/06/2003US20030041602 Process for production of nanoparticles and microparticles by spray freezing into liquid
03/06/2003CA2468466A1 Use of pregnane-diones or diols as neuropathic analgesic agents
1 ... 5544 5545 5546 5547 5548 5549 5550 5551 5552 5553 5554 5555 5556 5557 5558 5559 5560 5561 5562 5563 5564 ... 7860